Collegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month High – Should You Buy?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $44.94 and last traded at $44.84, with a volume of 562339 shares. The stock had previously closed at $43.53.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on COLL shares. HC Wainwright increased their price target on shares of Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Truist Financial lifted their target price on shares of Collegium Pharmaceutical from $45.00 to $48.00 and gave the company a “buy” rating in a report on Friday, November 7th. Needham & Company LLC reiterated a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Tuesday, October 28th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $44.25.

Collegium Pharmaceutical Stock Performance

The company has a market cap of $1.45 billion, a P/E ratio of 28.50 and a beta of 0.61. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.27 and a current ratio of 1.36. The firm has a 50 day moving average price of $36.21 and a 200-day moving average price of $33.29.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The firm had revenue of $135.55 million for the quarter. On average, research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 16,389 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $38.21, for a total transaction of $626,223.69. Following the completion of the sale, the executive vice president owned 103,613 shares in the company, valued at $3,959,052.73. The trade was a 13.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Colleen Tupper sold 30,000 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $40.53, for a total value of $1,215,900.00. Following the sale, the chief financial officer owned 126,667 shares of the company’s stock, valued at approximately $5,133,813.51. This trade represents a 19.15% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 63,867 shares of company stock worth $2,513,628. Insiders own 2.51% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several large investors have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. boosted its holdings in Collegium Pharmaceutical by 26.9% in the first quarter. Envestnet Asset Management Inc. now owns 30,892 shares of the specialty pharmaceutical company’s stock worth $922,000 after acquiring an additional 6,554 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in Collegium Pharmaceutical by 18.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 713,854 shares of the specialty pharmaceutical company’s stock worth $21,309,000 after buying an additional 109,655 shares in the last quarter. South Dakota Investment Council lifted its stake in shares of Collegium Pharmaceutical by 4.3% in the 1st quarter. South Dakota Investment Council now owns 34,316 shares of the specialty pharmaceutical company’s stock valued at $1,024,000 after purchasing an additional 1,400 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its position in Collegium Pharmaceutical by 2.4% in the first quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 124,671 shares of the specialty pharmaceutical company’s stock valued at $3,721,000 after purchasing an additional 2,895 shares during the period. Finally, KLP Kapitalforvaltning AS lifted its holdings in Collegium Pharmaceutical by 17.5% during the 1st quarter. KLP Kapitalforvaltning AS now owns 30,200 shares of the specialty pharmaceutical company’s stock worth $901,000 after buying an additional 4,500 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.